semaglutide diet plan what to eat and what to avoid Discover 43 semaglutide food ideas in 2026 A Semaglutide Diet Plan: To

It leads to reduced food intake and promotes weight loss through a decreased drive to eat

This is why GLP-1 medications are generally not recommended for individuals with a personal or family history of Medullary Thyroid Cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that predisposes people to certain endocrine tumours

Perimenopause or menopause symptoms

DataM expects that oral obesity medicines will prove themselves as one of the fastest-growing pockets owing to the move from specialist-driven injectable therapy to more primary care-oriented therapy

So Dr Maran advises to take pain in the stomach seriously and consult a good gastro surgeon who can easily diagnose if appendicitis is present.

Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record